Adicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical Study

Adicet Bio Inc ACET announced preclinical data highlighting ADI-270, an allogeneic "off-the-shelf" gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the Annual Meeting of the American Society of Gene & Cell Therapy.

Gamma delta T cells modified to express CD70 CAR were successfully generated and expanded without evident hindrances from CD70-mediated fratricide.

Also Read: Adicet Bio Shares Fall After Underwhelming Data From Non-Hodgkin's Lymphoma Study.

ADI-270 demonstrated preclinical proof-of-concept.

ADI-270 gamma delta 1 CAR T cells expressed a predominant naïve-like memory phenotype with potent in vitro cytotoxicity and production of proinflammatory cytokines against CD70+ tumor cell lines via multiple mechanisms.

ADI-270 showed significant inhibition of tumor growth in CD70+ tumor cell lines, which was maintained in the presence of TGF beta inhibitory factor, and exhibited improved resistance to killing by host T cell rejection.

ADI-270 also demonstrated marked biodistribution and infiltration into solid renal cell carcinoma tumor models.

Price Action: ACET shares are down 6.01% at $6.27 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!